Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor... see more

Recent & Breaking News (NDAQ:MGNX)

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 13, 2024

September 24, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - MGNX

Accesswire September 13, 2024

MGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 13, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. Lawsuit - MGNX

Accesswire September 13, 2024

MacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

PR Newswire September 13, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

PR Newswire September 13, 2024

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 12, 2024

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 12, 2024

The Schall Law Firm Invites Investors With Losses In MacroGenics, Inc. To Join A Securities Fraud Case

Accesswire September 12, 2024

MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX

Accesswire September 12, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

PR Newswire September 12, 2024

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 12, 2024

Class Action Filed Against MacroGenics, Inc. (MGNX) - September 24, 2024 Deadline to Join - Contact The Gross Law Firm

PR Newswire September 12, 2024

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 11, 2024

MacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Newsfile September 11, 2024

MacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 11, 2024

Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire September 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

Accesswire September 11, 2024

MacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Newsfile September 11, 2024

MacroGenics Inc May Have Committed Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

Accesswire September 11, 2024